Skip to content

AOCI at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
-$24K+4.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$1.8M-2,091%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$62K
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$479K-86.7%
TRV
Trevi Therapeutics, Inc.TRVI
-$190K-360%
PVL
Palvella TherapeuticsPVLA
$95K+3,267%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's AOCI?
Savara (SVRA) reported AOCI of -$429K in Q1 2026.
How has Savara's AOCI changed year-over-year?
Savara's AOCI increased by 32.1% year-over-year, from -$632K to -$429K.
What is the long-term trend for Savara's AOCI?
Over 5 years (2020 to 2025), Savara's AOCI has grown at a -37.9% compound annual growth rate (CAGR), from $942K to -$87K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.